Consensus EPS · Q2 2026
$5.71
Consensus revenue · Q2 2026
$11.7B
Analysts
14
Last reported
Jul 23, 2026
Analyst consensus
Based on estimates from 14 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $11.5B | $11.7B | $11.8B |
| EPS | $5.65 | $5.71 | $5.75 |
| EBITDA | $3.1B | $3.2B | $3.2B |
| EBIT | $2.3B | $2.4B | $2.4B |
| Net income | $2.1B | $2.1B | $2.1B |
- Revenue$11.7B
- EPS$5.71
- EBITDA$3.2B
- EBIT$2.4B
- Net income$2.1B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q2 2026 | $12B | $11.7B | +2.5% | $6.03 | $5.72 | +5.4% |
| Q1 2026 | $11B | $10.9B | +1.3% | $5.44 | $5.25 | +3.7% |
| Q4 2025 | $12.2B | $11.9B | +2.2% | $6.57 | $6.45 | +1.9% |
- Q2 2026+2.5%+5.4%
- Q1 2026+1.3%+3.7%
- Q4 2025+2.2%+1.9%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
No community consensus
No TickerLeague members predicted Thermo Fisher Scientific (TMO) Q2 2026 before it reported.
Analyst price target
Based on price targets from 4 analysts.
- Low
- $510.00
- Consensus
- $598.92
- Median
- $607.50
- High
- $683.00
- Current
- $568.26
- Upside
- +5.4%
Upside calculated vs most recent trading price of $568.26.
Analyst ratings
Consensus: Buy — based on 42 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 24, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Jul 24, 2026 | Barclays | maintain | Overweight | Overweight |
| Jul 6, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jun 3, 2026 | HSBC | downgrade | Buy | Hold |
| May 8, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| Apr 24, 2026 | Stifel | maintain | Buy | Buy |
| Apr 24, 2026 | Baird | maintain | Outperform | Outperform |
| Apr 14, 2026 | Barclays | maintain | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jan 30, 2026 | TD Cowen | maintain | Buy | Buy |
- Jul 24, 2026RBC CapitalSector Perform
- Jul 24, 2026BarclaysOverweight
- Jul 6, 2026Evercore ISI GroupOutperform
- Jun 3, 2026HSBCHold
- May 8, 2026Wells FargoOverweight
- Apr 24, 2026StifelBuy
- Apr 24, 2026BairdOutperform
- Apr 14, 2026BarclaysOverweight
- Apr 6, 2026Evercore ISI GroupOutperform
- Jan 30, 2026TD CowenBuy
Frequently asked questions
Thermo Fisher Scientific (TMO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks4.73% TTM
- Dividend Profile0.32% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History8 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.